



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

REGISTERED OFFICE, HEAD OFFICE & FACTORY :
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)
Tel: 0132-3242000, 3258400 Fax : 0132-2664200

11th February, 2016

The Manager – Listing
The Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai – 400001

BSE Scrip Code: 531207

Subject: Outcome of Board Meeting under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform you that in the meeting of the Board of Directors held on Thursday, February 11, 2016, following Resolutions were passed:

1. The Board considered and approved the Unaudited Financial Results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the quarter ending December 31, 2015.
2. The Board took note of Limited Review Report for the Quarter ending December 31, 2015 as placed by the Auditor of the Company.
3. The Board took note of Statement of Investor Complaints/Grievances given Under Regulation 13 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ending December 31, 2015.
4. The Board of Director authorize Mr. Ajai Goyal, Whole-Time Director of the Company, as Key Managerial Personnel in terms of Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s).

We hope you will find the same in order.

Kindly take the above information on your records.

Thanking you,

Sincerely,
For Raymed Labs Limited



Ajai Goyal
Whole Time Director
DIN: 02636418



Encl

CC: Ahmedabad Stock Exchange Limited

Life is Preciousand Raymed cares



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com **website :** www.raymedlabs.com

Tel. 0132-3242000

Unaudited Financial Results for the Quarter Ended on December 31, 2015

PART I							Rs. in Lacs
	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Year to Date Figures for Current Period	Year to Date Figures for the Previous Year	Previous Year
		31-12-2015	30-09-2015	31-12-2014	Ended 31-12-2015	Ended 31-12-2014	Ended 31-03-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
	Total Income from Operations (net)	-	-	-	-	-	-
2	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods,						
	(c) work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee expenses & benefits	0.23	0.23	0.15	0.68	0.85	1.00
	(e) Depreciation and amortisation expense	-	-	-	-	-	-
	(f) Other expenses	0.14	0.67	0.16	1.37	2.56	2.99
	Total Expenses	0.37	0.90	0.31	2.05	3.41	3.99
3	Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)	-0.37	-0.90	-0.31	-2.05	-3.41	-3.99
4	Other Income	0.54	0.54	0.54	1.62	1.62	2.16
5	Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)	0.17	-0.36	0.23	-0.43	-1.79	-1.83
6	Finance Costs	-	-	-	-	-	0.00
7	Profit/Loss from ordinary activities after finance costs but before exceptional items (5-6)	0.17	-0.36	0.23	-0.43	-1.79	-1.83
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7-8)	0.17	-0.36	0.23	-0.43	-1.79	-1.83
10	Tax Expense	-	-	-	-	-	-
11	Net Profit/ Loss from Ordinary Activities after Tax (9-10)	0.17	-0.36	0.23	-0.43	-1.79	-1.83
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13	Net Profit/ Loss for the period (11-12)	0.17	-0.36	0.23	-0.43	-1.79	-1.83
17	Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	427.35
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
19 i	Earning Per Share (before extraordinary items)	0.004	-0.008	0.005	-0.010	-0.042	-0.04
19 ii	Earning Per Share (after extraordinary items)	0.004	-0.008	0.005	-0.010	-0.042	-0.04



Life is Preciousand Raymed cares



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

PART II							
	Particulars	3 Months Ended 31-12-2015	Preceding 3 Months Ended 30-09-2015	Corresponding 3 Months Ended 31-12-2014 in the Previous Year	Year to Date Figures for Current Period Ended 31-12-2015	Year to Date Figures for the Previous Year Ended 31-12-2014	Previous Year Ended 31-03-2015
A PARTICULARS OF SHAREHOLDING							
1	Public Shareholding						
	- Number of shares	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450	30,61,450
	- Percentage of shareholding	71.64%	71.64%	71.64%	71.64%	71.64%	71.64%
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered						
	- Number of Shares	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050	12,12,050
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a% of the total share capital of the company)	28.36%	28.36%	28.36%	28.36%	28.36%	28.36%

Notes:

- 1 The unaudited financial statements for the quarter ended on December 31, 2015 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 11, 2016. The information presented above is extracted from the financial statement.
- 2 EPS has been calculated in accordance with AS-20 issued by ICAI.
- 3 The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- 4 Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- 5 No investor complaints were pending in the beginning and end of the quarter ended December 2015.

For Raymed Labs Limited

Ajai Goyal

Ajai Goyal
Place: Saharanpur
Date: 11-02-2016



Life is Preciousand Raymed cares



A. KAY. MEHRA & CO.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

To,
The Board of Directors
RAYMED LABS LTD

Limited review Report for the quarter ended December 31, 2015

We have reviewed the accompanying statement of unaudited financial results of RAYMED LABS LTD For the period ended December 31, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

For A Kay Mehra & Co
Chartered Accountants
(Firm Reg No. 050004C)



Deepak Suneja

CA Deepak Suneja

Partner

M.No. 501957

Place: Delhi

Date: February 11, 2016